Přehled publikační činnosti pracovníků CHL

Vybrané publikace s IF

Malikova I, Husakova M, Bilkova J, Brzezkova R, Hrachovinova I, Kvasnicka T. Thrombin Generation Decrease After LMWH Administration in an Antithrombin-Deficient Pregnant Woman With a Homozygous HBS II Mutation. Clin Appl Thromb Hemost. 2023;29:10760296231197174.

Malikova I, Husakova M, Bilkova J, Brzezkova R, Kvasnicka T. Thrombin Decrease in Thrombin Generation after Heparin Administration in a Homozygous Type II Heparin Binding Site Antithrombin-Deficient Pregnant Woman. Medical principles and practice : international journal of the Kuwait University, Health Science Centre. 2023:1.

Malikova I, Husakova M, Bilkova J, Brzezkova R, Hrachovinova I, Kvasnicka T. The Homozygous Type II Antithrombin Deficient Pregnant Woman Monitored by Thrombin Generation Assay. Clinical laboratory. 2023;69(10).

Vítek L, Jirásková A, Malíková I, Dostálová G, Eremiášová L, Danzig V, et al. Serum Bilirubin and Markers of Oxidative Stress and Inflammation in a Healthy Population and in Patients with Various Forms of Atherosclerosis. Antioxidants (Basel, Switzerland). 2022;11(11).

Kutac D, Bohonek M, Landova L, Staskova E, Blahutova M, Malikova I, et al. Cryopreservation of apheresis platelets treated with riboflavin and UV light. Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis. 2023;62(2):103580.

Řádek M, Babuňková E, Špaček M, Kvasnička T, Kvasnička J. Determination of Circulating Endothelial Cells and Endothelial Progenitor Cells Using Multicolor Flow Cytometry in Patients with Thrombophilia. Acta Haematol. 2019 Apr 17:1-7.

Visentin A, Chatzikonstantinou T, Scarfò L, Kapetanakis A, Demosthenous C, Karakatsoulis G; ERIC Group. The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL. Am J Hematol 2023 Sep 29. doi: 10.1002/ajh.27093.

Panovská A, Arpáš T, Šimkovič M, Špaček M, Papajík T, Lysák D, Bezděková L, Doubek M. Prevence a léčba kardiovaskulárních a krvácivých komplikací u nemocných s chronickou lymfocytární leukemií léčených inhibitory Brutonovy kinázy. Transfuze Hematol Dnes 2023;29(3):177-184.

Líkařová T, Špaček M. Inhibitory Brutonovy tyrosinkinázy a jejich současné postavení v léčbě chronické lymfocytární leukemie. Onkologie. 2023;17(3):192-196.

Špaček M, Smolej L, Šimkovič M, Nekvindová L, Křístková Z, Brychtová Y, Panovská A, Mašlejová S, Bezděková L, Écsiová D, Vodárek P, Zuchnická J, Mihályová J, Urbanová R, Turcsányi P, Lysák D, Novák J, Brejcha M, Líkařová T, Vodička P, Baranová J, Trněný M, and Doubek M, on behalf of Czech CLL Study Group. Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed / refractory chronic lymphocytic leukaemia: a real-world analysis from the Czech CLLEAR registry. Br J Haematol 2023;202(1):40-47. doi: 10.1111/bjh.18736.

Šimkovič M, Turcsányi P, Špaček M, Mihályová J, Ryznerová P, Maco M, Vodárek P, Écsiová D, Poul H, Móciková H, Zuchnická J, Panovská A, Lekaa M, Oršulová M, Prchlíková A, Stejskal L, Mašlejová S, Brychtová Y, Bezděková L, Papajík T, Lysák D, Trněný M, Smolej L, Doubek M. COVID-19 in patients with chronic lymphocytic leukemia: a multicenter analysis by the Czech CLL study group. Ann Hematol. 2023;27:1-7.

Kósa F, Nečasová T, Špaček M, Giannopoulos K, Hus I, Jurková T, Koriťáková E, Chrápavá M, Nováčková M, Katinová I, Krejčí D, Jujka A, Mátrai Z, Vályi-Nagy I, Robak T, Doubek M. Secondary malignancies and survival of FCR-treated patients with chronic lymphocytic leukemia in Central Europe. Cancer Med. 2023 Jan;12(2):1961-1971. doi: 10.1002/cam4.5033.

Antic D, Milic N, Chatzikonstantinou T, et al. Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL. J Hematol Oncol. 2022 Aug 26;15(1):116. doi: 10.1186/s13045-022-01333-0.

Stopka T, Minařík L, Dusilková N, Pešta M, Kulvait V, Špaček M, Zemanová Z, Kalousová M, Jonášová A. G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial. Blood Cancer J. 2022;12(7):105. doi: 10.1038/s41408-022-00698-2.

Chatzikonstantinou T, Kapetanakis A, Scarfò L, Karakatsoulis G, Allsup D, Cabrero AA, Andres M, Antic D, Baile M, Baliakas P, Bron D, Capasso A, Chatzileontiadou S, Cordoba R, Correa JG, Cuéllar-García C, De Paoli L, De Paolis MR, Del Poeta G, Demosthenous C, Dimou M, Donaldson D, Doubek M, Efstathopoulou M, Eichhorst B, El-Ashwah S, Enrico A, Espinet B, Farina L, Ferrari A, Foglietta M, Frederiksen H, Fürstenau M, García-Marco JA, García-Serra R, Gentile M, Gimeno E, Glenthøj A, Gomes da Silva M, Gutwein O, Hakobyan YK, Herishanu Y, Hernández-Rivas JÁ, Herold T, Innocenti I, Itchaki G, Jaksic O, Janssens A, Kalashnikova ОB, Kalicińska E, Karlsson LK, Kater AP, Kersting S, Labrador J, Lad D, Laurenti L, Levin MD, Lista E, Lopez-Garcia A, Malerba L, Marasca R, Marchetti M, Marquet J, Mattsson M, Mauro FR, Milosevic I, Mirás F, Morawska M, Motta M, Munir T, Murru R, Niemann CU, Rodrigues RN, Olivieri J, Orsucci L, Papaioannou M, Pavlovsky MA, Piskunova I, Popov VM, Quaglia FM, Quaresmini G, Qvist K, Reda G, Rigolin GM, Ruchlemer R, Saghumyan G, Shrestha A, Šimkovič M, Špaček M, Sportoletti P, Stanca O, Stavroyianni N, Tadmor T, Te Raa D, Tonino SH, Trentin L, Van Der Spek E, van Gelder M, van Kampen R, Varettoni M, Visentin A, Vitale C, Wasik-Szczepanek E, Wróbel T, San Segundo LY, Yassin M, Coscia M, Rambaldi A, Montserrat E, Foà R, Cuneo A, Stamatopoulos K, Ghia P. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. Leukemia. 2021 Nov 1 : 1–11. doi: 10.1038/s41375-021-01450-8

Seifert B, Balík M, Bártů V, Bezdíčková L, Černý V, Čierná-Peterová I, Čupka J, Dlouhý P, Halata D, Karen I, Kessler P, Koblížek V, Král N, Kvasnička T, Kvasnička J, Mucha C, Penka M, Svačina Š, Šeblová J, Špaček M, Trojánek M. Optimizing clinical approaches to COVID-19 patients in primary care. Cas Lek Cesk. 2021;160(4):119-125.

Hinzmann R, Militz D, Zima T, Špaček M, Storm H, Chapanduka Z, Hauss O. Real-world data from Europe and Africa suggest that accuracy of systems for self-monitoring of blood glucose is frequently impaired by low hematocrit. Diabetes Res Clin Pract. 2021 May 11;108860. doi: 10.1016/j.diabres.2021.108860

Smolej L, Špaček M, Pospíšilová Š, Jarošová M, Papajík T, Urbanová R, Šimkovič M, Lysák D, Brejcha M, Doubek M. Doporučení pro diagnostiku a léčbu chronické lymfocytární leukemie 2021. Transfuze Hematol. Dnes 2021;27(1):91-106.

Smolej L, Brychtová Y, Cmunt E, Doubek M, Špaček M, Belada D, Šimkovič M, Stejskal L, Zygulová I, Urbanová R, Brejcha M, Zuchnická J, Móciková H, Kozák T; Czech CLL Study Group. Low-dose fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long-term results of project Q-lite by the Czech CLL Study Group. Br J Haematol. 2021 May;193(4):769-778. doi: 10.1111/bjh.17373.

Smolej L, Turcsányi P, Kubová Z, Zuchnická J, Mihályová J, Šimkovič M, Vodárek P, Krčméryová M, Móciková H, Brejcha M, and Špaček M, for Czech CLL Study Group. External validation of International Prognostic Score for asymptomatic early-stage chronic lymphocytic leukaemia and proposal of an alternative score. Br J Haematol. 2021 Apr;193(1):133-137. doi: 10.1111/bjh.17074. Epub 2020 Sep 10.

Karolova J, Radek M, Helman K, Spacek M, Trneny M, Klener P. PD-1, PD-L1 and PD-L2 Expression in Mantle Cell Lymphoma and Healthy Population. Folia Biol (Praha). 2020;66(4):117-122.

Vockova P, Molinsky J, Klanova M, Karban J, Spacek M, Havranek O, Kupcova K, Kazantsev D, Trneny M, Klener P. CD31/PECAM-1 impacts engraftment, growth and spread of mantle cell lymphoma cells and positively correlates with extramedullary involvement. Leuk Lymphoma. 2020 Nov 25:1-8. doi: 10.1080/10428194.2020.1849678

Scarfò L, Chatzikonstantinou T, Rigolin GM, Quaresmini G, Motta M, Vitale C, Garcia-Marco JA, Hernández-Rivas JÁ, Mirás F, Baile M, Marquet J, Niemann CU, Reda G, Munir T, Gimeno E, Marchetti M, Quaglia FM, Varettoni M, Delgado J, Iyengar S, Janssens A, Marasca R, Ferrari A, Cuéllar-García C, Itchaki G, Špaček M, De Paoli L, Laurenti L, Levin MD, Lista E, Mauro FR, Šimkovič M, Van Der Spek E, Vandenberghe E, Trentin L, Wasik-Szczepanek E, Ruchlemer R, Bron D, De Paolis MR, Del Poeta G, Farina L, Foglietta M, Gentile M, Herishanu Y, Herold T, Jaksic O, Kater AP, Kersting S, Malerba L, Orsucci L, Popov VM, Sportoletti P, Yassin M, Pocali B, Barna G, Chiarenza A, Dos Santos G, Nikitin E, Andres M, Dimou M, Doubek M, Enrico A, Hakobyan Y, Kalashnikova O, Ortiz Pareja M, Papaioannou M, Rossi D, Shah N, Shrestha A, Stanca O, Stavroyianni N, Strugov V, Tam C, Zdrenghea M, Coscia M, Stamatopoulos K, Rossi G, Rambaldi A, Montserrat E, Foà R, Cuneo A, Ghia P., COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia. 2020 Sep;34(9):2354-2363. doi: 10.1038/s41375-020-0959-x. Epub 2020 Jul 9

Cuneo A, Mato AR, Rigolin GM, Piciocchi A, Gentile M, Laurenti L, Allan JN, Pagel JM, Brander DM, Hill BT, Winter A, Lamanna N, Tam CS, Jacobs R, Lansigan F, Barr PM, Shadman M, Skarbnik AP, Pu JJ, Sehgal AR, Schuster SJ, Shah NN, Ujjani CS, Roeker L, Orlandi EM, Billio A, Trentin L, Spacek M, Marchetti M, Tedeschi A, Ilariucci F, Gaidano G, Doubek M, Farina L, Molica S, Di Raimondo F, Coscia M, Mauro FR, de la Serna J, Medina Perez A, Ferrarini I, Cimino G, Cavallari M, Cucci R, Vignetti M, Foà R, Ghia P; GIMEMA, European Research Initiative (ERIC) on CLL, US study group. Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. Cancer Med. 2020 Nov;9(22):8468-8479. doi: 10.1002/cam4.3470.

Panovska A, Nemcova L, Nekvindova L, Spacek M, Simkovic M, Papajik T, Brejcha M, Lysak D, Zuchnicka J, Novak J, Starostka D, Poul H, Vrbacky F, Vodarek P, Urbanova R, Plevova K, Pospisilova S, Maslejova S, Brychtova Y, Koritakova E, Smolej L, Doubek M. Real-world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus chlorambucil, and rituximab plus bendamustine in the frontline treatment of chronic lymphocytic leukemia: The GO-CLLEAR Study by the Czech CLL Study Group. Hematol Oncol. 2020 Oct;38(4):509-516. doi: 10.1002/hon.2744.

Herishanu Y, Shaulov A, Fineman R, Bašić-Kinda S, Aviv A, Wasik-Szczepanek E, Jaksic O, Zdrenghea M, Greenbaum U, Mandac I, Simkovic M, Morawska M, Benjamini O, Spacek M, Nemets A, Bairey O, Trentin L, Ruchlemer R, Laurenti L, Stanca Ciocan O, Doubek M, Shvidel L, Dali N, Mirás F, De Meûter A, Dimou M, Mauro FR, Coscia M, Bumbea H, Szász R, Tadmor T, Gutwein O, Gentile M, Scarfò L, Tedeschi A, Sportoletti P, Gimeno Vázquez E, Marquet J, Assouline S, Papaioannou M, Braester A, Levato L, Gregor M, Rigolin GM, Loscertales J, Medina Perez A, Nijziel MR, Popov VM, Collado R, Slavutsky I, Itchaki G, Ringelstein S, Goldschmidt N, Perry C, Levi S, Polliack A, Ghia P. Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group. Am J Hematol. 2020 Feb 25.

Stranska K, Plevova K, Skuhrova Francova H, Skabrahova H, von Jagwitz-Biegnitz M, Radova L, Panovska A, Hrobkova S, Brychtova Y, Urbanova R, Smolej L, Simkovic M, Zuchnicka J, Mohammadova L, Spacek M, Mayer J, Pospisilova S, Doubek M. Profiling of biological and environmental risk factors in immunogenetic subgroups of chronic lymphocytic leukemia - Czech national study. Biomedical Papers-Olomouc 2020; 164(4):425-434.

Salles G, Bachy E, Smolej L, Simkovic M, Baseggio L, Panovska A, Besson H, Healy N, Garside J, Iraqi W, Diels J, Pick-Lauer C, Spacek M, Urbanova R, Lysak D, Hermans R, Lundbom J, Callet-Bauchu E, Doubek M. Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia. Ann Hematol. 2019 Dec;98(12):2749-2760.

Špaček M, Obrtlíková P, Hrobková S, Cmunt E, Karban J, Molinský J, Šimkovič M, Mociková H, Mohammadová L, Panovská A, Novák J, Trněný M, Smolej L, Doubek M. Prospective observational study in comorbid patients with chronic lymphocytic leukemia receiving first-line bendamustine with rituximab. Leuk Res 2019;79:17-21.

Rawstron AC, Kreuzer KA, Soosapilla A, Spacek M, Stehlikova O, Gambell P, McIver-Brown N, Villamor N, Psarra K, Arroz M, Milani R, de la Serna J, Cedena MT, Jaksic O, Nomdedeu J, Moreno C, Rigolin GM, Cuneo A, Johansen P, Johnsen HE, Rosenquist R, Niemann CU, Kern W, Westerman D, Trneny M, Mulligan S, Doubek M, Pospisilova S, Hillmen P, Oscier D, Hallek M, Ghia P, Montserrat E. Reproducible diagnosis of Chronic Lymphocytic Leukemia by flow cytometry: an European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) harmonisation project. Cytometry B Clin Cytom. 2018 Jan;94(1):121-128.

Vargova K, Pesta M, Obrtlikova P, Dusilkova N, Minarik L, Vargova J, Berkova A, Zemanova Z, Michalova K, Spacek M, Trneny M, Stopka T. MiR-155/miR-150 network regulates progression through the disease phases of chronic lymphocytic leukemia. Blood Cancer J. 2017 Jul 21;7(7):e585. doi: 10.1038/bcj.2017.63.

Rawstron AC, Fazi C, Agathangelidis A, Villamor N, Letestu R, Nomdedeu J, Palacio C, Stehlikova O, Kreuzer KA, Liptrot S, O'Brien D, de Tute RM, Marinov I, Hauwel M, Spacek M, Dobber J, Kater AP, Gambell P, Soosapilla A, Lozanski G, Brachtl G, Lin K, Boysen J, Hanson C, Jorgensen JL, Stetler-Stevenson M, Yuan C, Broome HE, Rassenti L, Craig F, Delgado J, Moreno C, Bosch F, Egle A, Doubek M, Pospisilova S, Mulligan S, Westerman D, Sanders CM, Emerson R, Robins HS, Kirsch I, Shanafelt T, Pettitt A, Kipps TJ, Wierda WG, Cymbalista F, Hallek M, Hillmen P, Montserrat E, Ghia P. A complementary role of multiparameter flow-cytometry and high-throughput sequencing for Minimal Residual Disease (MRD) detection in Chronic Lymphocytic Leukemia (CLL): an European Research Initiative on CLL (ERIC) study. Leukemia 2016;30(4):929-36.